Innate Pharma S.A. (NASDAQ:IPHA) Shares Sold by Optiver Holding B.V.

Optiver Holding B.V. lowered its holdings in Innate Pharma S.A. (NASDAQ:IPHA) by 63.5% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 81,796 shares of the company’s stock after selling 142,301 shares during the period. Optiver Holding B.V. owned approximately 0.10% of Innate Pharma worth $257,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the business. Balyasny Asset Management LLC purchased a new position in shares of Innate Pharma in the third quarter valued at $32,000. Jane Street Group LLC boosted its stake in shares of Innate Pharma by 156.3% in the first quarter. Jane Street Group LLC now owns 37,736 shares of the company’s stock valued at $127,000 after purchasing an additional 23,012 shares during the period. Exchange Traded Concepts LLC purchased a new position in shares of Innate Pharma in the second quarter valued at $133,000. Millennium Management LLC boosted its stake in shares of Innate Pharma by 389.8% in the fourth quarter. Millennium Management LLC now owns 71,684 shares of the company’s stock valued at $267,000 after purchasing an additional 57,050 shares during the period. Finally, BlackRock Inc. boosted its stake in shares of Innate Pharma by 27.4% in the first quarter. BlackRock Inc. now owns 504,408 shares of the company’s stock valued at $1,695,000 after purchasing an additional 108,335 shares during the period. Institutional investors and hedge funds own 0.29% of the company’s stock.

Innate Pharma Trading Up 2.4 %

NASDAQ IPHA opened at $2.51 on Tuesday. Innate Pharma S.A. has a 12 month low of $1.81 and a 12 month high of $3.97. The company’s fifty day moving average price is $2.52 and its two-hundred day moving average price is $2.85.

Analysts Set New Price Targets

IPHA has been the subject of several analyst reports. Citigroup decreased their target price on shares of Innate Pharma from $12.00 to $8.00 in a research note on Monday, September 18th. HC Wainwright restated a “buy” rating and issued a $11.50 target price on shares of Innate Pharma in a research note on Wednesday, November 15th.

About Innate Pharma

Innate Pharma SA, a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), an Anti-C5aR Antibody; IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager.